Redeye remains confident on the case but makes some further downward adjustments to our forecasts on the back of the Q2 report. The challenging market climate persisted in the second quarter and sales declined by 14% Y/Y. Still, Absolent is showing good resilience with EBITDA margins of 16%, adjusted for one-offs. The company’s near-term outlook continues to be cautious, prompting several efficiency measures to support growth and profitability.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/